A vs. MOH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and MOH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
A’s market capitalization of 34.48 billion USD is substantially larger than MOH’s 12.99 billion USD, indicating a significant difference in their market valuations.
A’s beta of 1.23 points to significantly higher volatility compared to MOH (beta: 0.57), suggesting A has greater potential for both gains and losses relative to market movements.
| Symbol | A | MOH |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Molina Healthcare, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Plans |
| CEO | Padraig McDonnell | Joseph Michael Zubretsky |
| Price | 121.38 USD | 239.58 USD |
| Market Cap | 34.48 billion USD | 12.99 billion USD |
| Beta | 1.23 | 0.57 |
| Exchange | NYSE | NYSE |
| IPO Date | November 18, 1999 | July 2, 2003 |
| ADR | No | No |
Historical Performance
This chart compares the performance of A and MOH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
A
19.46%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
MOH
25.54%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
MOH’s Return on Equity of 25.54% is exceptionally high, placing it well beyond the typical range for the Medical - Healthcare Plans industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
A
11.71%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Invested Capital of 11.71% signifies a highly effective use of its capital to generate profits when compared to its peers.
MOH
15.50%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
In the upper quartile for the Medical - Healthcare Plans industry, MOH’s Return on Invested Capital of 15.50% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
A
17.59%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 17.59% places A in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
MOH
2.81%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
A Net Profit Margin of 2.81% places MOH in the upper quartile for the Medical - Healthcare Plans industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
A
21.38%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 21.38% places A in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MOH
4.10%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
An Operating Profit Margin of 4.10% places MOH in the upper quartile for the Medical - Healthcare Plans industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | A | MOH |
|---|---|---|
| Return on Equity (TTM) | 19.46% | 25.54% |
| Return on Assets (TTM) | 9.59% | 7.18% |
| Return on Invested Capital (TTM) | 11.71% | 15.50% |
| Net Profit Margin (TTM) | 17.59% | 2.81% |
| Operating Profit Margin (TTM) | 21.38% | 4.10% |
| Gross Profit Margin (TTM) | 53.79% | 11.41% |
Financial Strength
Current Ratio
A
2.09
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
A’s Current Ratio of 2.09 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
MOH
1.63
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
MOH’s Current Ratio of 1.63 aligns with the median group of the Medical - Healthcare Plans industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
A
0.57
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
A’s Debt-to-Equity Ratio of 0.57 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MOH
0.87
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
MOH’s leverage is in the upper quartile of the Medical - Healthcare Plans industry, with a Debt-to-Equity Ratio of 0.87. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
A
-472.33
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
A has a negative Interest Coverage Ratio of -472.33. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
MOH
12.79
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
With an Interest Coverage Ratio of 12.79, MOH demonstrates a superior capacity to service its debt, placing it well above the typical range for the Medical - Healthcare Plans industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | A | MOH |
|---|---|---|
| Current Ratio (TTM) | 2.09 | 1.63 |
| Quick Ratio (TTM) | 1.60 | 1.63 |
| Debt-to-Equity Ratio (TTM) | 0.57 | 0.87 |
| Debt-to-Asset Ratio (TTM) | 0.29 | 0.23 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.43 | -0.57 |
| Interest Coverage Ratio (TTM) | -472.33 | 12.79 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for A and MOH. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
A
0.81%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.81%, A offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
MOH
0.00%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
MOH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
A
23.76%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
MOH
0.00%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
MOH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | A | MOH |
|---|---|---|
| Dividend Yield (TTM) | 0.81% | 0.00% |
| Dividend Payout Ratio (TTM) | 23.76% | 0.00% |
Valuation
Price-to-Earnings Ratio
A
29.67
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
A’s P/E Ratio of 29.67 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
MOH
11.12
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
MOH’s P/E Ratio of 11.12 is below the typical range for the Medical - Healthcare Plans industry. This may indicate that the stock is potentially undervalued, or it could reflect market concerns about the company’s future prospects.
Forward P/E to Growth Ratio
A
3.80
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
A Forward PEG Ratio of 3.80 places A in the upper quartile for the Medical - Diagnostics & Research industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
MOH
0.72
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
In the lower quartile for the Medical - Healthcare Plans industry, MOH’s Forward PEG Ratio of 0.72 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.
Price-to-Sales Ratio
A
5.20
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
A’s P/S Ratio of 5.20 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MOH
0.31
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
MOH’s P/S Ratio of 0.31 aligns with the market consensus for the Medical - Healthcare Plans industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
A
5.64
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
MOH
3.04
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
MOH’s P/B Ratio of 3.04 is within the conventional range for the Medical - Healthcare Plans industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | A | MOH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 29.67 | 11.12 |
| Forward PEG Ratio (TTM) | 3.80 | 0.72 |
| Price-to-Sales Ratio (P/S, TTM) | 5.20 | 0.31 |
| Price-to-Book Ratio (P/B, TTM) | 5.64 | 3.04 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 24.63 | 24.73 |
| EV-to-EBITDA (TTM) | 25.95 | 6.25 |
| EV-to-Sales (TTM) | 5.51 | 0.28 |